New Cycle, New Landscape, New Opportunities: Embracing the '23+1' Provincial Alliance Suture Tender Ecosystem
Surgical sutures, as the indispensable “precision link” in surgical procedures, play a vital role in bridging the hope for healing and safeguarding patients’ quality of life. Nanjing Pulimon has long been dedicated to clinical practice with a focus on surgical suturing, driving breakthroughs and quality upgrades in domestically produced suture technologies through a decade of craftsmanship and innovation. The company is committed to providing safer and more reliable medical solutions for patients. To join forces with like-minded partners in serving clinical needs and expanding market reach, Nanjing Pulimon will soon launch a nationwide roadshow of business investment and exchange meetings for its suture products. Starting from December 2025, these events will be held successively across all provinces (municipalities, autonomous regions, and the Xinjiang Production and Construction Corps) involved in centralized procurement, including Liaoning Province, Tianjin Municipality, Hebei Province, Shanxi Province, Inner Mongolia Autonomous Region, Jilin Province, Heilongjiang Province, Anhui Province, Jiangxi Province, Henan Province, Hubei Province, Guangxi Zhuang Autonomous Region, Hainan Province, Chongqing Municipality, Sichuan Province, Guizhou Province, Yunnan Province, Tibet Autonomous Region, Shaanxi Province, Gansu Province, Qinghai Province, Ningxia Hui Autonomous Region, Xinjiang Uygur Autonomous Region, and the Xinjiang Production and Construction Corps. We sincerely invite partners in the medical device industry to attend these meetings, discuss collaboration opportunities, explore future prospects together, and jointly create a new future for the industry!
(Scan the QR code to register)
Nanjing Pulimon’s outstanding performance in this centralized procurement represents not only authoritative recognition but also a market-driven choice. Amidst fierce competition, Pulimon has already secured its future; winning the bid is not the end goal. The company will continue to invest in R&D, seizing opportunities for fair competition among domestic enterprises and achieving “overtaking on the bend.” The optimization of centralized procurement rules has provided valuable breakthrough opportunities for Chinese manufacturers that prioritize innovation and quality. Guided by its mission to revolutionize domestic suturing technology, Nanjing Pulimon remains committed to clinical needs, leveraging its robust R&D system and agile industrialization capabilities to build a highly competitive product portfolio and establish insurmountable technological barriers.
In 2016, the company was established, laying out its R&D strategy for sutures and initiating multiple suture product development projects;
From 2018 to 2019, four Class II medical device registration certificates were approved, leading to the launch of a series of polyamide (nylon) non-absorbable self-closing surgical sutures (Su Xie Zhu Zhun 20182020290), non-absorbable self-closing surgical sutures with needles (Su Xie Zhu Zhun 20192021213), non-absorbable surgical sutures (Su Xie Zhu Zhun 20182020289), and non-absorbable surgical sutures with needles (Su Xie Zhu Zhun 20192021214). Meanwhile, clinical studies for Class III suture products were initiated.
In 2020, two Class III medical device registration certificates were approved, and the company successfully launched its PPDO (polydioxanone) knotless barbed suture product (National Medical Device Registration No. 20203020610) and PPDO (polydioxanone) monofilament suture (National Medical Device Registration No. 20203020320).
In 2022, launched an innovative leak-proof, non-absorbable polypropylene (PP) suture (Jiangsu Medical Device Registration No. 20222021700);
In 2023, launched rapidly absorbable, knotless barbed sutures made of PGA-PCL (polyglycolic acid-polycaprolactone) material (National Medical Device Registration No. 20233020032);
In 2024, three domestically produced antibacterial barbed sutures were fully launched in the market: embossed polydioxanone fishbone suture (NMPA Registration No. 20243021186), triclosan-coated polydioxanone antibacterial barbed suture (NMPA Registration No. 20243022047), and triclosan-coated glycolide-caprolactone antibacterial barbed suture (NMPA Registration No. 20243021966), along with triclosan-coated glycolide-L-lactide antibacterial suture (NMPA Registration No. 20243022048).
Throughout its journey, Nanjing Primed has remained deeply committed to addressing actual clinical needs. By leveraging continuously iterative innovation and delivering stable, reliable product quality, the company has demonstrated the value and strength of Chinese medical device manufacturers amidst the wave of volume-based procurement. Through strategic system-wide layout, Nanjing Primed has continuously expanded its portfolio of high-end medical consumables, including surgical sutures. It is dedicated to meeting the demands of increasingly complex clinical scenarios with comprehensive and precise suturing solutions, thereby fulfilling its commitment to deeply respond to clinical needs and providing reliable assurance for healthcare institutions and patients.
New Cycle, New Landscape, New Opportunities. Nanjing Pulimon has been successfully selected as the top-ranked bidder in Group A within the procurement alliance led by Liaoning Province, comprising 24 provinces (municipalities, autonomous regions, and the Xinjiang Production and Construction Corps). Fully prepared and ready to embark on this journey, we sincerely invite like-minded channel partners with a regional focus to join forces with us. With comprehensive preparations in place, we aim to shape the future together. We look forward to partnering with you to pioneer a new chapter in surgical suturing! Scan the QR code below to reserve your seat at the event immediately.
(Scan the QR code to register)
